TABLE 3.
Clinical trials in glioblastoma (GBM) using chimeric antigen receptor-T (CAR-T).
| Title | Condition or Disease | Intervention/Treatment | NCT Number | Status | Status Phase |
| Pilot study of autologous anti-EGFRvIII CAR-T cells in recurrent glioblastoma multiforme | Glioblastoma multiforme | Biological: anti-EGFRvIII CAR-T cells drug: cyclophosphamide Drug: Fludarabine | NCT02844062 | Phase I | |
| Pilot study of B7-H3 CAR-T in treating patients with recurrent and refractory glioblastoma | Recurrent glioblastoma Refractory glioblastoma | Drug: B7-H3 CAR-T Drug: Temozolomide | NCT04385173 | Recruiting | Phase I |
| B7-H3 CAR-T for recurrent or refractory glioblastoma | Recurrent glioblastoma Refractory glioblastoma | Drug: Temozolomide Biological: B7-H3 CAR-T | NCT04077866 | Not yet recruiting | Phase I, II |
| CD147-CAR-T cells in patients with recurrent malignant glioma | Recurrent glioblastoma CD147 positive | Biological: CD147-CAR-T | NCT04045847 | Active, not recruiting | Early phase I |
| CART-EGFRvIII + pembrolizumab in GBM | Glioblastoma | Biological: CART-EGFRvIII T cells Biological: Pembrolizumab | NCT03726515 | Active, not recruiting | Phase I |
| EGFRvIII CAR-T cells for newly diagnosed WHO grade IV malignant glioma | Glioblastoma Gliosarcoma | Biological: EGFRvIII CAR-T cells | NCT02664363 | Terminated | Phase I |
| Chimeric antigen receptor (CAR- T) cells with a chlorotoxin tumor-targeting domain for the treatment of recurrent or progressive glioblastoma | Recurrent glioblastoma Recurrent malignant glioma recurrent WHO grade II glioma recurrent WHO grade III glioma | Biological: Chlorotoxin (EQ)-CD28-CD3zeta-CD19t-expressing CAR-TTlymphocytes NCI SYs | NCT04214392 | Recluting | Phase I |
| IL13Ralpha2-targeted chimeric antigen receptor (CAR-T) T cells with or without nivolumab and ipilimumab in treating patients with recurrent or refractory glioblastoma | Recurrent glioblastoma Refractory glioblastoma | Biological: IL13Ralpha2-specific Hinge-optimized 4-1BB-co-stimulatory CAR/Truncated CD19-expressing autologous TN/MEM Cells Biological: Ipilimumab Biological: Nivolumab | NCT04003649 | Recluting | Phase I |
| Autologous T cells redirected to EGFRVIII-with a chimeric antigen receptor in patients with EGFRVIII+ glioblastoma | Patients with residual or reccurent EGFRvIII+ glioma | Biological: CART-EGFRvIII T cells | NCT02209376 | Terminated Result | Phase I |
| NKG2D-based CAR-T-cells Immunotherapy for patient with r/r NKG2DL+ solid tumors | Hepatocellular carcinoma Glioblastoma Medulloblastoma Colon cancer | Biological: NKG2D-based CAR-T-cells | NCT04270461 | Not yet recruiting | Phase I |
| Pilot study of autologous chimeric switch receptor modified T Cells in recurrent glioblastoma multiforme | Glioblastoma multiforme | Biological: Anti-PD-L1 CSR T cells Drug: Cyclophosphamide Drug: Fludarabine | NCT02937844 | Phase I | |
| Intracerebral EGFR-vIII CAR-T cells for recurrent GBM | Recurrent glioblastoma Recurrent gliosarcoma | Biological: EGFRvIII-CARs | NCT03283631 | Recluting | Phase I |
| Combination of immunization and radiotherapy for malignant gliomas (In situ Vac1) | High grade glioma Glioblastoma Glioma of brainstem Glioma Malignant | Combination Product: Combined immune adjuvants and radiation | NCT03392545 | Recluting | Phase I |
| CAR-T cell receptor immunotherapy targeting EGFRvIII for patients with malignant gliomas expressing EGFRvIII | Malignant glioma Glioblastoma Brain cancer Gliosarcoma | Biological: Epidermal growth factor receptor (EGFRv)III Chimeric antigen receptor (CAR) transduced PBL Drug: Aldesleukin Drug: Fludarabine Drug: Cyclophosphamide | NCT01454596 | Completed | Phase I, II |
| Immunogene-modified T (IgT) cells against glioblastoma multiforme | Glioblastoma multiforme of brain glioblastoma multiforme | Biological: Antigen-specific IgT cells | NCT03170141 | Enrolling by invitation | Phase I |
| CMV-specific cytotoxic T lymphocytes expressing CAR-T targeting HER2 in patients with GBM (HERT-GBM) | Glioblastoma multiforme | Biological: HER.CAR-TCMV-specific CTLs | NCT01109095 | Completed | Phase I |
| Genetically modified T-cells in treating patients with recurrent or refractory malignant glioma | Malignant glioma Refractory brain neoplasm Recurrent brain neoplasm Glioblastoma | Biological: IL13Rα2-specific, hinge-optimized, 41BB-costimulatory CAR/truncated CD19-expressing Autologous T lymphocytes Biological: Vaccine Therapy | NCT02208362 | Recluting | Phase I |
| Memory-enriched T cells in treating patients with recurrent or refractory grade III-IV glioma | Glioblastoma HER2/Neu positive Malignant glioma Recurrent glioma Refractory glioma WHO grade III glioma | Biological: CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T-lymphocytes Biological: CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes | NCT03389230 | Recluting | Phase I |
Summarized in the Table are the ongoing clinical trials present on ClinicalTrials.gov searching the keywords “glioblastoma multiforme” and “CAR-T.” The research has been done adding the following filters: “Not yet recruiting”; “Recruiting”; “Enrolling by invitation”; “Active, not recruiting”; “Suspended”; “Terminate”; “Completed”; “Withdrawn”; “Unknown status”; “The research has been performed on October 21st, 2020.”